Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR2 | P30518 | 14/20 | 0.59 |
| ▸ | AVPR1A | P37288 | 11/20 | 0.59 |
| ▸ | OXTR | P30559 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 3/20 | 0.42 |
| ▸ | RAB9A | P51151 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8564133 | 0.91 | AVPR2 (0.49) | AVPR2AVPR1A | |
| SCHEMBL8557265 | 0.91 | AVPR2 (0.58) | AVPR2AVPR1AOXTRNPC1RAB9A | |
| SCHEMBL8556938 | 0.88 | AVPR2 (0.56) | AVPR2AVPR1AOXTR | |
| SCHEMBL8559867 | 0.87 | RAB9A (0.47) | AVPR2AVPR1ARAB9A | |
| SCHEMBL8556908 | 0.87 | RAB9A (0.47) | AVPR2AVPR1ANPC1RAB9A | |
| SCHEMBL8561421 | 0.87 | AVPR2 (0.56) | AVPR2AVPR1AOXTR | |
| SCHEMBL8557390 | 0.87 | AVPR2 (0.52) | AVPR2AVPR1AOXTR | |
| SCHEMBL8558373 | 0.86 | AVPR2 (0.59) | AVPR2AVPR1AOXTR | |
| SCHEMBL8561432 | 0.85 | AVPR2 (0.55) | AVPR2AVPR1ANPC1RAB9AALDH1A1 | |
| SCHEMBL8564681 | 0.85 | AVPR2 (0.42) | AVPR2AVPR1AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0640592-B1 | N-acylated tricyclic azaheterorings useful as vasopressin antagonists | AMERICAN CYANAMID CO (US) | 1998-12-30 | — | — | EP | disclosed |